The Effect of Walking Exercises in Patients With Atrial Fibrillation
NCT ID: NCT05189691
Last Updated: 2023-05-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
78 participants
INTERVENTIONAL
2022-04-04
2023-02-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exercise Effects on Atrial Fibrillation
NCT06607510
Study of the Effect of Exercise Training on Patients in Atrial Fibrillation
NCT01367197
The Effect of High-Intensity Interval Training on Glucose Variability and Atrial Fibrillation Symptoms
NCT04190212
Impact of Pre-Ablation Prehabilitation on Clinical Outcomes and Cardiorespiratory Fitness in Atrial Fibrillation Patients
NCT07270757
Aerobic Interval Training in Patients With Atrial Fibrillation
NCT01325675
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Method: The project was planned as a prospective, single-blind, randomized controlled experimental type. The research will be carried out in Konya Necmettin Erbakan University Meram Medical Faculty Hospital Cardiology Department between March - October 2022. In determining the sample size, based on the studies in the literature, considering possible losses, and with 95% confidence and 80% test power, the minimum number of samples in each group was determined as 39 and a total of 78. In the collection of study data, the application steps of the Behavior Change Model and Behavior Change Wheel will be discussed first. Patient identification form, Short Form 36 (SF 36), University of Toronto Atrial Fibrillation Severity Scale (AFSS), Walk Tracking Chart and Pedometer (Pedometer) will be used as data collection tools.
Management: Data will be collected by the assistant researcher at the beginning of the study, at the 4th and 12th weeks, in the new service building of the Necmettin Erbakan University Meram Medical Faculty Hospital, in the echocardiography laboratory doctor's room.
In the preliminary application of the research, a questionnaire will be applied to 10 participants. In addition, to test the step counting accuracy of the pedometers according to the walking style, 5 participants will be visually counted and confirmed by the assistant researcher while walking at their own pace in the closed corridor.
Application
* When the implementation phase of the research begins, the purpose of the research will be explained and written/verbal consent will be obtained by interviewing individuals with AF sent by a cardiology specialist at the Necmettin Erbakan University Meram Medical Faculty Hospital Cardiology Clinic or outpatient clinic. Consent will be taken in the echocardiography laboratory doctor's room, where data are collected. Individuals who agree to participate in the research will be evaluated in terms of inclusion and exclusion criteria.
* As part of current clinical practice, all participants' blood pressure (BP), height and weight will be measured by the assistant researcher at study initiation. The patient identification form, the Toronto AF Symptom Severity Scale and Short Form 36 (SF-36) will be evaluated by interview method at baseline.
* Afterwards, an interview will be held by the assistant researcher about the lifestyle changes that are effective in all CV diseases and the health benefits of regular physical activity. Participants will be informed about the study and their written consent will be obtained.
* Participants included in the intervention group during the implementation phase of the study will be told that physical activity will start with 10-15 minutes initially, and then continue until participants reach a duration of 30 or 60 minutes, 3 times a week. Participants will be instructed that the goal is to exceed the previous number of steps each time.
* Participants will be informed that if participants feel fatigue or palpitations throughout the day, participants can exercise the next day.
* If participants have trouble/shortness of breath, chest pain, palpitation complaints during walking, he/she will be told to take a break from walking and rest. In addition to the controls of the participants with ongoing symptoms, the study will be carried out under the supervision of a cardiologist throughout the study.
* In order to ensure regular follow-up and control of the participants, a pedometer will be given and an explanation will be given about its use, and the participants will be asked to mark them on the walking tracking chart. After each exercise, the assistant researcher will explain to the participants how to keep a record.
* The initial step count value will be recorded as the number of steps recorded on the first day the participant used the pedometer.
* Participants will be instructed to put on the pedometer before walking and not to take it off during the walk. It will be emphasized that rhythmic walking is important for the pedometer to count correctly.
* Phone calls will be made once a week in order to motivate the participants, and participants will be informed that participants can call the assistant researcher for consultation when needed.
* Participants in the control group will receive standard clinical care.
* BP measurement, body mass index (BMI), Toronto AF Symptom Severity Scale and Short Form 36 (SF-36) scales will be evaluated by the assistant researcher at the 4th week and at the end of the 12th week in the experimental and control groups.
* In addition, the number of steps recorded continuously in the experimental group will be evaluated for analysis, taking into account the last measurements of the 4th and 12th weeks.
Widespread effect: Studies have shown that physical activity increases the quality of life, exercise capacity, heart rate control, peak maximum oxygen consumption (VO2 max) value, and reduces symptoms in AF patients. General population studies show that mild to moderate physical activity is primarily and secondarily protective against AF. Given the well-defined effects of prolonged exercise on the risk of AF, it has been reported that the optimal exercise interval for adults may be 20 minutes of aerobics, walking or cycling, 3 to 5 times per week. However, achieving less than recommended levels of physical activity was associated with a reduced risk of mortality compared to inactive patients, suggesting that even below recommended levels of physical activity, it is better than nothing for secondary prevention of AF.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
behavior change and walking exercise
A nurse-led interview will be held about the health benefits of lifestyle change and regular physical activity, which are effective in all CV diseases.Initially starting with 10-15 minutes of physical activity, it will continue until it reaches a duration of 30 or 60 minutes, 3 times a week. The goal is to exceed the previous number of steps each time. A pedometer will be used to ensure regular follow-up and control, and the number of steps will be marked on the walking tracking chart. They will be told how to keep a record after each exercise. A weekly phone call will be made to motivate the patient and the researcher will be informed that they can call.Blood pressure measurement, BMI, Toronto AF Symptom Severity Scale, Short Form 36 (SF-36) scales and continuously recorded step counts will be evaluated at week 0, 4 and at the end of week 12.
walking exercise
Initially starting with 10-15 minutes of physical activity, it will continue until it reaches a duration of 30 or 60 minutes, 3 times a week. The goal is to exceed the previous number of steps each time. If they feel fatigue or palpitations during the day, they can do their exercises the next day. If there are complaints of shortness of breath/shortness of breath, chest pain, palpitation during walking, he should take a break from walking and rest. A pedometer will be used to ensure regular follow-up and control, and the number of steps will be marked on the walking tracking chart. They will be told how to keep a record after each exercise. A weekly phone call will be made to motivate the patient and the researcher will be informed that they can call.
behavior change
A nurse-led interview will be held about the health benefits of lifestyle change and regular physical activity, which are effective in all CV diseases.Blood pressure measurement, BMI, Toronto AF Symptom Severity Scale and Short Form 36 (SF-36) scales will be evaluated at week 0, 4 and at the end of week 12.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
walking exercise
Initially starting with 10-15 minutes of physical activity, it will continue until it reaches a duration of 30 or 60 minutes, 3 times a week. The goal is to exceed the previous number of steps each time. If they feel fatigue or palpitations during the day, they can do their exercises the next day. If there are complaints of shortness of breath/shortness of breath, chest pain, palpitation during walking, he should take a break from walking and rest. A pedometer will be used to ensure regular follow-up and control, and the number of steps will be marked on the walking tracking chart. They will be told how to keep a record after each exercise. A weekly phone call will be made to motivate the patient and the researcher will be informed that they can call.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Volunteer
* Sign the informed consent form
* Diagnosed with AF
* Speak and understand Turkish
Exclusion Criteria
* Not being literate
* Having cognitive and affective problems (vision, hearing impairment, delirium, dementia, depression, schizophrenia, bipolar disorder, etc.)
* Having had a myocardial infarction in the last month,
* Unstable clinical condition (uncontrolled cardiac arrhythmia, symptomatic severe aortic stenosis or other valvular disease, decompensated symptomatic heart failure and acute myocarditis or pericarditis),
* Presence of disability that will prevent physical activity (Orthopedic reasons or other disabilities).
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Necmettin Erbakan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ayse Ucar
Lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Selda ARSLAN, Phd
Role: STUDY_DIRECTOR
Necmettin Erbakan University Faculty of Nursing
Ayşe Uçar, MSC
Role: PRINCIPAL_INVESTIGATOR
Necmettin Erbakan University Faculty of Nursing
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Necmettin Erbakan University
Konya, Meram, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21149003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.